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BACKGROUND
Tofersen is an antisense oligonucleotide that mediates the degradation of super-
oxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intra-
thecal administration of tofersen is being studied for the treatment of amyotrophic 
lateral sclerosis (ALS) due to SOD1 mutations.
METHODS
We conducted a phase 1–2 ascending-dose trial evaluating tofersen in adults with 
ALS due to SOD1 mutations. In each dose cohort (20, 40, 60, or 100 mg), participants 
were randomly assigned in a 3:1 ratio to receive five doses of tofersen or placebo, 
administered intrathecally for 12 weeks. The primary outcomes were safety and phar-
macokinetics. The secondary outcome was the change from baseline in the cerebro-
spinal fluid (CSF) SOD1 concentration at day 85. Clinical function and vital capacity 
were measured.
RESULTS
A total of 50 participants underwent randomization and were included in the analy-
ses; 48 participants received all five planned doses. Lumbar puncture–related ad-
verse events were observed in most participants. Elevations in CSF white-cell count 
and protein were reported as adverse events in 4 and 5 participants, respectively, who 
received tofersen. Among participants who received tofersen, one died from pulmo-
nary embolus on day 137, and one from respiratory failure on day 152; one partici-
pant in the placebo group died from respiratory failure on day 52. The difference 
at day 85 in the change from baseline in the CSF SOD1 concentration between the 
tofersen groups and the placebo group was 2 percentage points (95% confidence 
interval [CI], −18 to 27) for the 20-mg dose, −25 percentage points (95% CI, −40 to 
−5) for the 40-mg dose, −19 percentage points (95% CI, −35 to 2) for the 60-mg 
dose, and −33 percentage points (95% CI, −47 to −16) for the 100-mg dose.
CONCLUSIONS
In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the 
highest concentration of tofersen administered intrathecally over a period of 12 
weeks. CSF pleocytosis occurred in some participants receiving tofersen. Lumbar 
puncture–related adverse events were observed in most participants. (Funded by 
Biogen; ClinicalTrials.gov number, NCT02623699; EudraCT number, 2015 - 004098 - 33.)
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U
p to 2% of all cases of amyotrophic 
lateral sclerosis (ALS) result from muta-
tions in the gene encoding superoxide 
dismutase 1 (SOD1).1,2 More than 180 different 
SOD1 mutations have been identified in ALS.3-5 
Disease penetration, progression rate, and prog-
nosis are variable and may be mutation-specific.6,7
The mechanisms by which mutations in SOD1 
cause degeneration of motor neurons in genetic 
ALS are not fully understood; a toxic gain of func-
tion has been considered to be the most likely 
mechanism in ALS caused by SOD1 mutations.1,8-13 
Lowering the concentration of mutant SOD1 pro-
tein may be a potential target for therapeutic in-
tervention.6,14 Antisense oligonucleotides (ASOs) 
have been generally safe for the treatment of other 
diseases, including spinal muscular atrophy.15,16 
ASOs targeting SOD1 messenger RNA (mRNA) 
transcripts prolonged survival and improved mo-
tor performance in rodent models of ALS caused 
by SOD1 mutations and reduced SOD1 protein 
concentrations in nonhuman primates.9
Tofersen (BIIB067) is an ASO that is under 
investigation for the treatment of ALS caused by 
SOD1 mutations. Tofersen has been designed to 
mediate RNase H–dependent degradation of 
SOD1 mRNA to reduce the synthesis of SOD1 
protein.9,17,18 We are conducting a three-part trial: 
parts A (single ascending dose)19 and B (multiple 
ascending dose) have been completed, and part C 
is ongoing. Here, we describe the results from 
part B, a multiple ascending-dose trial that evalu-
ated the safety, pharmacokinetics, and pharma-
codynamics of tofersen in adults with ALS.
Me thods
Oversight
We conducted this trial in accordance with the 
Good Clinical Practice guidelines of the Interna-
tional Council for Harmonisation, and the trial 
protocol (available with the full text of this ar-
ticle at NEJM.org) was approved by the relevant 
ethics committees. There was no data and safety 
monitoring board for this portion of the trial. 
Written informed consent was provided by the 
participants or their legal representatives.
The sponsor (Biogen) and the academic au-
thors designed the trial. Biogen provided tofersen 
and placebo and oversaw the trial. Data were col-
lected by the investigators and analyzed by the 
sponsor. The first draft of the manuscript was 
written by the first author and the senior indus-
try author; medical writing assistance was paid for 
by the sponsor. The sponsor reviewed the manu-
script and provided feedback to the authors. The 
authors had full editorial control of the manu-
script and provided their final approval of all 
content. All the authors vouch for the accuracy 
and completeness of the data, for the fidelity of 
the trial to the protocol, and for the complete 
reporting of adverse events. Confidentiality agree-
ments were in place between the authors and the 
sponsor.
Participants
The trial included adults who had muscle weak-
ness that had been attributed to ALS on the basis 
of conventional criteria and a documented SOD1 
mutation. Inclusion criteria included normal co-
agulation variables and a forced vital capacity of 
at least 50% of the predicted value as adjusted 
for sex, age, and height. Participants who were 
receiving riluzole were required to maintain a 
stable dose, whereas patients who were receiving 
edaravone or were anticipated to receive edara-
vone were excluded from the trial. (Riluzole and 
edaravone are drugs used in the treatment of ALS). 
Full details of the inclusion and exclusion criteria 
are provided in the protocol.
Trial Design
This phase 1–2, randomized, double-blind, pla-
cebo-controlled trial was conducted at 18 sites in 
the United States, Canada, and four countries in 
Western Europe (Belgium, France, Germany, and 
the United Kingdom) beginning in January 2016 
(Fig. S1 in the Supplementary Appendix, avail-
able at NEJM.org). The participating investiga-
tors are listed according to country in Section S1 
in the Supplementary Appendix. Participants were 
followed for up to 31 weeks, which comprised a 
screening period of up to 7 weeks followed by a 
12-week intervention period and a 12-week fol-
low-up (Fig. S1).
Participants were assigned to one of four 
dose cohorts (20, 40, 60, or 100 mg), which were 
assessed sequentially. Progression of the trial to 
the next dose-level cohort was based on a blinded 
review of safety and pharmacokinetic data from 
the preceding cohorts by the sponsor and the 
investigators. Each dose-level cohort included 12 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF SHEFFIELD on July 27, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;2 nejm.org July 9, 2020 111
Tofersen for SOD1 ALS
participants who had been randomly assigned by 
means of interactive response technology in a 3:1 
ratio to receive tofersen or placebo (consisting of 
artificial cerebrospinal fluid [CSF]) as a lumbar 
intrathecal bolus injection; details of the injec-
tion method are provided in the protocol. If a 
participant withdrew from the trial before com-
pleting the final follow-up visit, the sample size 
could be increased by 1 at the discretion of the 
sponsor. No participants would be removed from 
analyses. All participants who withdrew and 
those who completed the trial would be included 
in the analyses. A single dose of tofersen or pla-
cebo was administered on days 1, 15, 29, 57, and 
85 (Fig. S1).
Outcomes
Primary outcomes were the incidence of adverse 
events and serious adverse events; abnormalities 
in clinical laboratory assessments and vital signs; 
physical examination including cranial nerves, 
coordination and cerebellar function, reflexes, mo-
tor function, and Mini–Mental State Examination; 
electrocardiograms; and tofersen pharmacokinetic 
measures in plasma and CSF. The secondary 
outcome was the change from baseline in the 
SOD1 protein concentration in CSF at day 85. 
The concentration was assessed with the use of 
a commercially available enzyme-linked immuno-
sorbent assay kit that was qualified by the con-
tract research organization (Covance) for quanti-
fication of SOD1 protein in CSF (Thermo Fisher 
Scientific).
Exploratory outcomes included changes from 
baseline in the total score on the Amyotrophic 
Lateral Sclerosis Functional Rating Scale–Revised 
(ALSFRS-R; 12 items in four domains of func-
tion are measured, each scored on a scale from 
0 to 4, with higher scores indicating better func-
tion), the percentage of the predicted slow vital 
capacity, the handheld dynamometry megascore 
(which assesses strength in 16 muscle groups in 
the arms and legs; z-score normalization is ap-
plied to the scores, with lower scores indicating 
worse function), and neurofilament concentrations 
(phosphorylated neurofilament heavy chains and 
a post hoc analysis of neurofilament light chains) 
(Section S2). A subgroup of participants with 
fast-progressing disease was defined post hoc for 
further analysis as described in the Statistical 
Analysis subsection, below. One staff member at 
each site consistently performed the ALSFRS-R 
and remained unaware of the trial-group assign-
ments and the results of other assessments. The 
concentrations of neurofilament light chains were 
assessed with the use of the Simoa NF-light Ad-
vantage assay (Quanterix), and concentrations of 
phosphorylated neurofilament heavy chains with 
the use of the Simple Plex Ella immunoassay 
(ProteinSimple).
Statistical Analysis
A 25% reduction in the CSF SOD1 protein concen-
tration was estimated to exceed both the SOD1 
assay variability and the longitudinal biovariability 
of CSF SOD1 as measured in humans. We calcu-
lated that 12 participants (9 to receive tofersen 
and 3 to receive placebo) in each of the four dose 
cohorts would be needed for the trial to have at 
least 80 to 99% power to detect differences in 
the reduction in the CSF SOD1 concentration 
(tofersen vs. placebo) between 12% and 25% at 
a 10% significance level. This sample-size calcu-
lation assumed a pooled standard deviation of 
0.11 (natural log). The interim analysis that is 
described in the statistical analysis plan (avail-
able with the protocol) was conducted on all data 
up to the day 85 visit for 11 of the 12 partici-
pants in the 100-mg dose cohort to permit plan-
ning for the phase 3 trial (the 12th participant 
had not competed day 85 of the study). The re-
sults presented here reflect data from the final 
analysis.
The modified intention-to-treat population, 
which was defined as all the participants who 
had undergone randomization and received at 
least part of one dose of tofersen or placebo, was 
also the safety population. Assessments of clini-
cal function, pharmacokinetics, pharmacodynam-
ics, and biomarkers included participants who had 
at least one relevant measurement after receipt of 
the dose.
Safety, clinical, pharmacokinetic, pharmaco-
dynamic, and exploratory outcomes were sum-
marized according to trial visit and according to 
dose with the use of descriptive statistics. Par-
ticipants who received placebo were combined 
across all cohorts for all summaries and analy-
ses. Postbaseline missing measurements for the 
SOD1 concentration, ALSFRS-R, the slow vital ca-
pacity, and the neurofilament concentrations were 
imputed with the use of a mixed model for re-
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peated measures; summary statistics for the hand-
held dynamometry megascore were calculated 
on the basis of the last observation carried for-
ward (Section S3). All the outcomes are reported 
with descriptive statistics, without P values; results 
are presented as point estimates with 95% con-
fidence intervals that were not adjusted for multi-
plicity, and therefore no inferences can be made. 
For slow vital capacity, the value associated with 
the maximum (best) effort at the visit was ana-
lyzed, regardless of acceptability according to 
American Thoracic Society guidelines. All the 
statistical analyses were performed with SAS soft-
ware, version 9.4 or higher (SAS Institute).
A fast-progression subgroup was defined post 
hoc for the purpose of analysis. Participants in 
the fast-progression subgroup had a SOD1 muta-
tion that was characterized as involving a fast-
progressing disease course (from a prespecified 
list of 10 mutations associated with a mean dis-
ease duration of ≤3 years) (Section S4 and Table 
S1), in addition to having a decrease in the pre-
randomization slope of the ALSFRS-R score of at 
least 0.2 points per month. Participants who did 
not meet this definition for fast-progressing dis-
ease were included in the “other” subgroup for 
post hoc analysis.
R esult s
Characteristics of the Participants
From November 7, 2016, to July 17, 2018, a total 
of 55 participants underwent screening, and 50 
were enrolled in the trial (Fig. S2). (We in-
creased the sample size from 48 to 50 to account 
for 2 participants who withdrew during the in-
tervention period; 1 participant in the placebo 
group died, and 1 in the 20-mg dose group with-
drew consent and was then lost to follow-up.) A 
total of 12 participants were assigned to receive 
placebo across the dose cohorts; among partici-
pants assigned to receive tofersen, 10 were as-
signed to the 20-mg dose group, 9 to the 40-mg 
dose group, 9 to the 60-mg dose group, and 10 to 
the 100-mg dose group. Two participants received 
an initial dose in a single-dose study (part A of 
this study) and subsequently enrolled in the cur-
rent multiple-dose trial after washout periods of 
32 weeks and 42 weeks. All the participants had 
a documented SOD1 mutation, reported limb pa-
resis at the onset of the illness, and received at 
least one dose of tofersen or placebo. Two partici-
pants who discontinued the trial were replaced. A 
total of 48 participants received all five planned 
doses. Participants who met the definition for 




Tofersen, 20 mg 
(N = 10)
Tofersen, 40 mg 
(N = 9)
Tofersen, 60 mg 
(N = 9)
Tofersen, 100 mg 
(N = 10)
number of participants (percent)
Any adverse event 12 (100) 10 (100) 9 (100) 9 (100) 10 (100)
Headache 7 (58) 4 (40) 2 (22) 4 (44) 6 (60)
Procedural pain 5 (42) 4 (40) 1 (11) 4 (44) 7 (70)
Post–lumbar puncture syndrome 3 (25) 4 (40) 3 (33) 3 (33) 3 (30)
Fall 3 (25) 3 (30) 3 (33) 2 (22) 5 (50)
Back pain 0 1 (10) 1 (11) 1 (11) 5 (50)
Nasopharyngitis 1 (8) 2 (20) 1 (11) 3 (33) 1 (10)
Upper respiratory tract infection 0 4 (40) 0 2 (22) 0
CSF protein concentration in-
creased
1 (8) 0 0 4 (44) 1 (10)
CSF white-cell count increased 0 0 1 (11) 3 (33) 0
Pain in arm or leg 2 (17) 0 1 (11) 0 3 (30)
Dizziness 3 (25) 0 0 0 1 (10)
Neck pain 3 (25) 0 0 1 (11) 0
*  The placebo group includes all the participants who had been assigned to receive placebo in any dose-matched cohort. CSF denotes cere-
brospinal fluid.
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the fast-progression subgroup were identified post 
hoc: 1 participant each at the tofersen dose levels 
of 20 mg and 40 mg, 2 participants at the 60-mg 
dose level, and 4 participants each at the 100-mg 
dose level and in the placebo group.
The characteristics of the participants at 
baseline that were related to disease progression 
(time since treatment onset and prerandomization 
slope of ALSFRS-R score) were balanced in the 
100-mg dose group and the placebo group, a 
finding that was consistent with the proportion 
of participants with fast progression in each co-
hort. However, the characteristics of the partici-
pants at baseline were not well balanced between 
the other tofersen dose groups and the placebo 
group. Regarding baseline characteristics other 
than those related to disease progression, the pla-
cebo group had a higher proportion of men, a 
lower percentage of participants receiving riluzole, 
a lower percentage of the predicted slow vital ca-
pacity, a higher handheld dynamometry mega-
score, and a lower SOD1 concentration in CSF than 
the 100-mg dose group (Table S2).
Safety and Adverse Events
All 50 participants were included in the safety 
analyses, and all the participants reported hav-
ing one or more adverse events. The most com-
mon adverse events among the 38 participants 
who received one or more doses of tofersen were 
headache (in 16 participants), procedural pain 
(in 16), post–lumbar puncture syndrome (in 13), 
and falls (in 13) (Table 1).
Five participants who received tofersen and 
two who received placebo had serious adverse 
events (Table 2). Three deaths occurred: one in 
the placebo group during the intervention period 
(respiratory failure related to ALS on day 52), 
one in the 20-mg dose group during follow-up 
(pulmonary embolism on day 137), and one in 
the 60-mg dose group during follow-up (respira-
tory failure related to ALS on day 152). One par-




Tofersen, 20 mg 
(N = 10)
Tofersen, 40 mg 
(N = 9)
Tofersen, 60 mg 
(N = 9)
Tofersen, 100 mg 
(N = 10)
number of participants (percent)
Grade†
1: mild 5 (42) 3 (30) 4 (44) 4 (44) 4 (40)
2: moderate 3 (25) 5 (50) 4 (44) 2 (22) 6 (60)
3: severe or medically significant 3 (25) 1 (10) 1 (11) 2 (22) 0
4: life-threatening 0 0 0 0 0
5: death related to adverse event 1 (8) 1 (10) 0 1 (11) 0
Event related to placebo or tofersen‡ 0 2 (20) 2 (22) 6 (67) 4 (40)
Event related to lumbar puncture‡ 9 (75) 8 (80) 7 (78) 8 (89) 9 (90)
Serious event 2 (17) 2 (20) 1 (11) 2 (22) 0
Serious event related to placebo or 
tofersen‡
0 0 0 1 (11) 0
Serious event leading to discontin-
uation of placebo or tofersen
1 (8) 0 0 0 0
Serious event leading to interrup-
tion of trial regimen
0 0 0 0 0
Serious event leading to withdraw-
al from trial
1 (8) 1 (10) 0 1 (11) 0
Death 1 (8) 1 (10) 0 1 (11) 0
*  The severity of adverse events and serious adverse events was graded according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4. Participants may have had more than one event in each category. The placebo group includes all the 
participants who had been assigned to receive placebo in any dose-matched cohort.
†  Each participant was counted once at the maximum grade of adverse event.
‡  Events related to placebo or tofersen (as determined in a blinded fashion), lumber puncture, or both were determined by the trial investiga-
tor.
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ticipant withdrew consent after receiving two 
doses of tofersen (in the 20-mg dose group) and 
discontinued the trial owing to disease progres-
sion prohibiting travel, and one participant in 
the placebo group withdrew consent after com-
pleting the intervention period.
At baseline and during the trial, an elevated 
CSF protein concentration or CSF pleocytosis (or 
both) was observed. In the combined placebo 
group, 1 of 12 participants (8%) had at least one 
CSF white-cell count of more than 10 cells per 
cubic millimeter, as compared with 16 of 38 
participants (42%) in the combined tofersen 
groups, with a maximum observed value of 144 
white cells per cubic millimeter. Elevations in 
CSF white-cell count and protein were reported 
as adverse events in 4 and 5 participants, respec-
tively, who received tofersen; 1 participant who 
received placebo had an adverse event of elevated 
CSF protein concentration. There was no clear 
association between higher doses of tofersen or 
placebo or longer duration of exposure and greater 
CSF pleocytosis or elevated protein concentrations 
(Fig. S3). None of these adverse events or CSF 
abnormalities (that were not considered to be ad-
verse events) led to trial discontinuation. Pharma-
cokinetic data are summarized in Section S5 and 
Figure S4.
SOD1 Reduction in CSF
The changes from baseline in the total SOD1 pro-
tein concentrations in CSF are presented in Fig-
ure 1. The geometric mean SOD1 concentration in 
CSF at baseline among participants who received 
tofersen was 79.9 ng per milliliter in the 20-mg 
dose group, 140.9 ng per milliliter in the 40-mg 
dose group, 102.5 ng per milliliter in the 60-mg 
dose group, and 139.8 ng per milliliter in the 
100-mg dose group; among participants who re-
ceived placebo, the concentration was 84.6 ng per 
milliliter. The geometric mean ratios of the SOD1 
protein concentrations among participants who 
received tofersen decreased from baseline to day 
85 by 1% in the 20-mg dose group, by 27% in the 
40-mg dose group, by 21% in the 60-mg dose 
group, and by 36% in the 100-mg dose group; 
among participants who received placebo, the 
ratio decreased by 3%. The difference in the ratio 
between the geometric mean value at day 85 and 
the baseline value of CSF SOD1 concentration 
between the tofersen groups and the placebo 
group was 2 percentage points (95% confidence 
interval [CI], −18 to 27) for the 20-mg dose 
group, −25 percentage points (95% CI, −40 to −5) 
for the 40-mg dose group, −19 percentage points 
(95% CI, −35 to 2) for the 60-mg dose group, 
and −33 percentage points (95% CI, −47 to −16) 
for the 100-mg dose group (Table S3). The base-
line concentrations and the magnitude of SOD1 
reduction in CSF were generally similar in the 
fast-progression subgroup and in the participants 
in the 100-mg dose group who were in the other 
subgroup. In an analysis that included only the 
36 participants across all the tofersen groups 
and the placebo group who completed the trial 
to day 169, the geometric mean SOD1 concentra-
tions in CSF were higher at day 169 than at day 85 
(Fig. S5).
Exploratory Outcomes
Results regarding clinical function (as assessed 
by the total ALSFRS-R score), respiratory function 
(as assessed by the percent predicted slow vital 
capacity), and muscle strength (as assessed by the 
handheld dynamometry megascore) are shown 
Figure 1. Effect of Tofersen Treatment on Total Superoxide Dismutase 1 
(SOD1) Protein Concentrations in Cerebrospinal Fluid.
The geometric mean ratio between the baseline value and the values at the 
specified time points are shown. Geometric mean ratios were calculated 
with the use of the least-squares method. I bars indicate 95% confidence 
intervals. In the combined placebo group, there was one anomaly for a ce-
rebrospinal fluid sample obtained at day 15; the result was below the limit 
of quantitation and was noted as being missing data. All missing data were 
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Least-squares mean change in percentage of predicted 
slow vital capacity (95% CI) — percentage points








































Mean change in handheld dynamometry megascore — 
points†
At day 22 −0.14±0.27 NA −0.06±0.23 −0.10±0.10 0.17±0.56
At day 92 −0.26±0.42 −0.14±0.20 −0.02±0.30 −0.16±0.26 −0.03±0.18
*  Plus–minus values are means ±SD. Clinical function was assessed with the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R), which measures 12 items in four 
domains of function, each scored on a scale from 0 to 4, with higher scores indicating better function. Respiratory function was assessed as the percentage of the predicted slow vital 
capacity. Muscle strength was assessed with the handheld dynamometry megascore, which assesses strength in 16 muscle groups in the arms and legs; z-score normalization was ap-
plied to scores, with lower scores indicating worse function. Changes in the ALSFRS-R score and the percentage of the predicted slow vital capacity are shown as least-squares means, 
and changes in the handheld dynamometry megascore are raw means. Because of the absence of a plan for adjustment for multiple comparisons, point estimates and multiplicity un-
adjusted confidence intervals are presented, from which no inferences can be made. NA denotes not available.
†  Because of the timing of the protocol amendment to obtain the handheld dynamometry megascore at day 22, no participants in cohort 5 (in which participants received placebo or 20 
mg of tofersen) had data for this score at this visit. Data were available for nine participants in the placebo group (i.e., those in other dose-matched cohorts) and for no participants in 
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in Table 3 and in Figures S6 through S9. Among 
the 10 participants who received tofersen in the 
100-mg dose group, the least-squares mean 
ALSFRS-R score at day 85 changed from baseline 
by −1.19 points (95% CI, −4.67 to 2.29), as com-
pared with a change of −5.63 points (95% CI, 
−8.90 to −2.36) among the 12 participants in the 
overall placebo group (Fig. 2). In the fast-pro-
gression subgroup, the ALSFRS-R score at day 85 
changed from baseline by 0.84 points (95% CI, 
−5.58 to 7.26) in the group that received 100 mg 
of tofersen, as compared with −16.73 points 
(95% CI, −23.28 to −10.18) in the placebo group.
With regard to the percentage of the pre-
dicted slow vital capacity in the 100-mg tofersen 
group, the least-squares mean percent at day 85 
changed from baseline by −7.08 percentage points 
(95% CI, −14.69 to 0.54), as compared with −14.46 
percentage points (95% CI, −21.79 to −7.12) in 
the overall placebo group (Fig. 2). In the fast-
progression subgroup, the percentage of the pre-
dicted slow vital capacity at day 85 changed from 
baseline by −8.62 percentage points (95% CI, 
−20.90 to 3.66) in the 100-mg dose group, as com-
pared with −30.31 percentage points (95% CI, 
−43.28 to −17.34) in the placebo group.
The mean change from baseline in the hand-
held dynamometry megascore at day 92 was 
−0.03±0.18 in the 100-mg tofersen dose group, 
as compared with −0.26±0.42 in the overall pla-
cebo group (Fig. 2). In the fast-progression sub-
group, the handheld dynamometry megascore 
changed from baseline at day 92 by 0.01±0.14 
points in the 100-mg dose group, as compared 
with −0.52±0.42 points in the placebo group.
Neurofilaments
The baseline neurofilament concentrations were 
at least 3.5 times as high in the fast-progression 
subgroup as in the other subgroup. The concen-
trations of phosphorylated neurofilament heavy 
chains and neurofilament light chains in plasma 
and CSF were largely unchanged during the in-
tervention period among the 12 participants in 
the placebo group at day 85, whereas among the 
10 participants who received 100 mg of tofersen, 
the concentrations decreased from baseline to 
day 85. Data are shown in Figures S10 through 
S12. Changes in the plasma and CSF concentra-
tions of phosphorylated neurofilament heavy 
chains and neurofilament light chains from day 
85 to day 169 are shown in Figures S13 and S14.
Discussion
In this trial of the SOD-1 mRNA-targeting ASO 
tofersen, adverse events were headache, proce-
dural pain, post–lumbar puncture syndrome, 
falls, back pain, pain in an arm or leg, dizziness, 
and neck pain, many of which were attributable 
to the lumbar puncture that was required for 
administration of tofersen or placebo. Increased 
CSF protein and white-cell counts were also ob-
served. The cause of CSF pleocytosis and protein 
elevations remains unclear. Although myelitis 
with sensory and motor deficits was not seen in 
this trial, the clinical syndrome has been observed 
in the context of tofersen administration (unpub-
lished data from the ongoing phase 3 [part C] 
portion of our trial and the long-term extension 
study [ClinicalTrials.gov number, NCT03070119]). 
The underlying cause of myelitis and the rela-
Figure 2 (facing page). Change from Baseline and Indi-
vidual Traces for the Total Amyotrophic Lateral Sclero-
sis Functional Rating Scale–Revised (ALSFRS-R) Score, 
the Percentage of Predicted Slow Vital Capacity, and 
Handheld Dynamometry Megascore.
Panel A shows individual values for the ALSFRS-R 
scores, the percentage of the predicted slow vital ca-
pacity, and handheld dynamometry megascores for all 
participants over time. The ALSFRS-R measures 12 
items in four domains of function, each scored on a 
scale from 0 to 4, with higher scores indicating better 
function. Handheld dynamometry measures strength 
in 16 muscle groups in the arms and legs; z-score nor-
malization was applied to scores, with lower scores in-
dicating worse function. Postbaseline missing values 
were imputed with the use of a mixed model for repeat-
ed measures for the ALSFRS-R score and the percent-
age of the predicted slow vital capacity; the last-obser-
vation-carried-forward method was used for the 
handheld dynamometry megascore. Baseline values 
were not carried forward, which resulted in missing 
data at day 22 for three participants in the placebo 
group (one in the fast-progression subgroup and two in 
the other subgroup, which included participants who 
did not meet the criteria for fast-progressing disease). 
The two subgroups were defined post hoc, and no con-
clusions can be drawn from these data. Panel B shows 
the least-squares (LS) mean total ALSFRS-R scores, the 
LS mean percentage of the predicted slow vital capaci-
ty, and the raw mean handheld dynamometry mega-
score in the 100-mg dose group and the placebo group, 
overall and in the two subgroups. In the graphs for the 
ALSFRS-R score and slow vital capacity, I bars indicate 
95% confidence intervals; in the handheld dynamome-
try megascore graphs, I bars indicate 1 SD.
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tionship to CSF pleocytosis and protein eleva-
tions are unknown. Changes in CSF variables 
and any manifestations of central nervous system 
inflammation are being monitored in part C of 
our trial and in the ongoing extension study.
The reduction from baseline in the total CSF 
SOD1 concentration was 3% in the placebo group 
and 36% in the group that received 100 mg of 
tofersen (the highest-dose group), with reduc-
tions in the lower-dose tofersen groups ranging 
from 1% to 27%. There was no multiplicity ad-
justment of confidence intervals for the CSF SOD1 
analyses, so no quantitative inferences can be 
made from these data. The highest concentra-
tions of tofersen in plasma and CSF were ob-
served with the 100-mg dose of tofersen. In post 
hoc analyses, there were no apparent differences 
in the baseline concentrations or magnitude of 
total reduction in the SOD1 concentration in 
CSF between participants with fast-progressing 
disease and other participants. In a finding that 
was possibly consistent with the half-life of SOD1 
protein (approximately 30 days in humans),20 the 
decrease in the SOD1 protein concentration was 
most apparent after 57 days. Data from animal 
models9 suggest that ASOs can lower SOD1 pro-
tein concentrations by more than 75% in the 
spinal cord, but it is unknown how the reduction 
in the SOD1 concentration in CSF in the current 
trial translates into a reduction of SOD1 concen-
tration in central nervous system parenchymal 
tissues.
This trial was not powered to test an effect on 
clinical or biologic measures beyond the reduc-
tion in SOD1 concentration in CSF. With regard 
to some exploratory outcomes, there may have 
been evidence of a slowing in the decrease in the 
ALSFRS-R score, the slow vital capacity, and the 
handheld dynamometry megascore with the 100-
mg dose of tofersen, although no conclusions can 
be drawn from these descriptive outcomes. With 
cessation of the 100-mg dose of tofersen, small-
er decreases in the SOD1 concentration in CSF, 
neurofilament light chains, and phosphorylated 
neurofilament heavy chains and greater decreases 
in the ALSFRS-R score were observed than during 
the intervention period.
Limitations of this early trial of tofersen in 
participants with ALS caused by SOD1 mutations 
were the small number of participants, the short 
duration of treatment and follow-up, the explor-
atory nature of the efficacy outcomes, and the 
post hoc methods for defining the fast-progres-
sion subgroup as compared with the other sub-
group. The safety and efficacy of tofersen are being 
evaluated in a phase 3, randomized, double-blind, 
placebo-controlled trial (ClinicalTrials.gov num-
ber, NCT02623699) and its long-term extension 
study (NCT03070119).
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